HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin.
VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTCPINK:HAVLF) (FSE:5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is proud to announce the harvest of its first crop of psilocybin-containing mushrooms from their growing and production facility in Jamaica.
Working with its partner, GMP manufacturer P.A. Benjamin in Kingston, the Company will export the harvested psilocybin to Canada where it will be tested for safety and quality control through its lab partner, Delic Labs.
“This is the moment we have been tirelessly working towards,” says HAVN Life CEO, Tim Moore. “We’ve been aggressively meeting the targets in our strategic roadmap and having this last piece in place with DELIC Labs will enable HAVN Life to become the first and top choice for product supply globally,” he adds.
Founded by award-winning chemist, Dr. Markus Roggen, and University of British Columbia Professor, Dr. Glenn Sammis, Delic Labs is a federally-authorized psilocybin and cannabis research laboratory-one of a handful of licensed psilocybin research labs in Canada. Delic Labs is one of the leading facilities in the world focused on QA/QC and safety testing for psilocybin and other psychedelic compounds. HAVN Life’s partnership with Delic Labs will facilitate the supply of product to the Company’s research and clinical partners, marking a very important step in HAVN Life’s strategy to produce quality-controlled, standardized product for research and clinical trials in North America, the Caribbean Community and Common Market (CARICOM) and Europe.
“Delic Labs is delighted to partner with HAVN on some of the world’s first psilocybin mushroom testing. Our lab has significantly built out its analytical and research capabilities to offer quality and safety testing to the psychedelic industry.” says Dr. Markus Roggen. “Psilocybin mushrooms are exciting and challenging botanicals with major medical potential. We are honored to have HAVN’s trust as their quality and safety testing partner in such a ground-breaking new industry.”
With this first harvest, HAVN Life will be able to begin supplying product to partners around the world, establishing the Company as an early mover in the ability to supply
companies with high-quality, naturally derived psilocybin as markets open up around the globe.
“Having been in Jamaica since March setting up the HAVN Labs facility, this first harvest feels celebratory after an intense period of work,” says Dr. Ivan Casselman, Chief Psychedelic Officer at HAVN Life. “We are now very focused on delivering product to our supply partners and developing our own APIs going forward,” he adds.
On Behalf of The Board of DirectorsTim MooreChief Executive Officer
About HAVN Life Sciences Inc. HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.
Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
Purchase our products and find out more at yourhavnlife.com , and follow us on Facebook , Twitter , Instagram and Youtube .
About Delic Labs Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.
Contact:Investor Relations: ir@HAVNlife.com 604 359 0060Media: savi@emergence-creative.com 647-896-8078
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.
